A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial
2025TrialsJournalOpen access
10.1186/s13063-025-09317-4Full text0 citations